- Release Date: 16/07/24 09:01
- Summary: Record FY24 driven by strong revenue growth & deal progress
- Price Sensitive: Yes
- Download Document 125.81KB
- Forums
- ASX - By Stock
- RTH
- Ann: Record FY24 driven by strong revenue growth & deal progress
Ann: Record FY24 driven by strong revenue growth & deal progress
Featured News
Add RTH (ASX) to my watchlist
|
|||||
Last
$1.30 |
Change
0.020(1.56%) |
Mkt cap ! $60.96M |
Open | High | Low | Value | Volume |
$1.29 | $1.34 | $1.28 | $60.19K | 45.27K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 6965 | $1.27 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.30 | 5877 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 5791 | 1.260 |
1 | 903 | 1.250 |
1 | 6145 | 1.225 |
1 | 7500 | 1.220 |
1 | 1250 | 1.170 |
Price($) | Vol. | No. |
---|---|---|
1.300 | 5877 | 1 |
1.340 | 2352 | 1 |
1.345 | 390 | 1 |
1.380 | 19900 | 1 |
1.390 | 10017 | 1 |
Last trade - 11.07am 16/07/2024 (20 minute delay) ? |
Featured News
RTH (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, CEO / Non-Exec Director
James Graham / Dr Alan Dunton
CEO / Non-Exec Director
SPONSORED BY The Market Online